PubRank

H Kim Lyerly

Author PubWeight™ 97.61‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002 2.65
2 Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol 2005 2.31
3 A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005 2.26
4 Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008 2.13
5 Use of tablet personal computers for sensitive patient-reported information. J Support Oncol 2009 1.73
6 An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 2010 1.71
7 Electronic patient-reported data capture as a foundation of rapid learning cancer care. Med Care 2010 1.67
8 Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data. Health Serv Res 2008 1.65
9 Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med 2012 1.59
10 The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 2009 1.58
11 Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res 2011 1.58
12 Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 2004 1.40
13 The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008 1.39
14 Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med 2007 1.33
15 Dendritic cell-based immunotherapy. Int Rev Immunol 2006 1.30
16 Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005 1.28
17 CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 2010 1.26
18 Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res Treat 2012 1.21
19 An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res 2013 1.18
20 Minimization of heatwave morbidity and mortality. Am J Prev Med 2013 1.16
21 Accelerated partial breast irradiation after conservative surgery for breast cancer. Ann Surg 2004 1.15
22 Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res 2011 1.15
23 Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther 2007 1.12
24 Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med 2007 1.11
25 Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res 2012 1.09
26 CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther 2007 1.07
27 Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem Biophys Res Commun 2005 1.07
28 A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013 1.03
29 Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest 2013 1.02
30 Histological and molecular evaluation of patient-derived colorectal cancer explants. PLoS One 2012 1.01
31 Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients. Support Care Cancer 2010 1.01
32 Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002 1.00
33 Translational Research Working Group developmental pathway for immune response modifiers. Clin Cancer Res 2008 1.00
34 Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunol Immunother 2010 0.98
35 Constitutive internalization of the leucine-rich G protein-coupled receptor-5 (LGR5) to the trans-Golgi network. J Biol Chem 2013 0.97
36 Identification of select glucocorticoids as Smoothened agonists: potential utility for regenerative medicine. Proc Natl Acad Sci U S A 2010 0.97
37 The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol 2003 0.96
38 Dendritic cell vaccines. Front Biosci 2007 0.95
39 Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study. Psychooncology 2011 0.95
40 Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003 0.95
41 An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. Clin Cancer Res 2010 0.94
42 Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. Breast Cancer Res Treat 2011 0.94
43 MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res 2011 0.93
44 Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer 2010 0.93
45 ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 2011 0.91
46 Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med 2014 0.91
47 Current status of adoptive immunotherapy of malignancies. Expert Opin Biol Ther 2002 0.91
48 NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother 2005 0.91
49 A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. Breast Cancer Res 2014 0.90
50 Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol 2002 0.89
51 Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol 2005 0.88
52 Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother 2013 0.88
53 Immune signatures predict prognosis in localized cancer. Cancer Invest 2010 0.88
54 Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002 0.88
55 Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. Int Immunol 2005 0.87
56 Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. Breast Cancer Res 2012 0.87
57 The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 2002 0.86
58 Gene therapy for lung cancer. J Cell Biochem 2006 0.85
59 Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes. Expert Opin Biol Ther 2002 0.84
60 Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. Chem Biol 2013 0.84
61 Small molecule modulators of Wnt/β-catenin signaling. Bioorg Med Chem Lett 2013 0.84
62 CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother 2015 0.84
63 Dendritic cell maturation in active immunotherapy strategies. Expert Opin Biol Ther 2002 0.83
64 Recent clinical progress in virus-based therapies for cancer. Expert Opin Biol Ther 2006 0.83
65 HER2 dendritic cell vaccines. Clin Breast Cancer 2003 0.83
66 Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Res 2010 0.83
67 Current immunotherapeutic strategies in colon cancer. Surg Oncol Clin N Am 2007 0.82
68 Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Clin Cancer Res 2009 0.82
69 Role of natural killer cell function in dendritic cell-based vaccines. Expert Rev Vaccines 2006 0.82
70 MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. J Proteomics 2011 0.82
71 Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer 2012 0.80
72 Global role of the immune system in identifying cancer initiation and limiting disease progression. J Clin Oncol 2005 0.80
73 Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells. Clin Transl Oncol 2012 0.80
74 Immunologic targeting of FOXP3 in inflammatory breast cancer cells. PLoS One 2013 0.80
75 Depletion of human regulatory T cells. Methods Mol Biol 2011 0.79
76 Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling. Bioorg Med Chem 2012 0.79
77 The insecticide synergist piperonyl butoxide inhibits hedgehog signaling: assessing chemical risks. Toxicol Sci 2012 0.79
78 Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. J Immunother 2015 0.79
79 Immunotherapy of surgical malignancies. Curr Probl Surg 2004 0.79
80 Biomarkers and correlative endpoints for immunotherapy trials. Am Soc Clin Oncol Educ Book 2013 0.78
81 Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling. PLoS One 2012 0.78
82 Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. Semin Oncol 2012 0.78
83 Regulation of hedgehog signaling by Myc-interacting zinc finger protein 1, Miz1. PLoS One 2013 0.77
84 Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. J Hematother Stem Cell Res 2002 0.77
85 CEA loaded dendritic cell vaccines. Cancer Chemother Biol Response Modif 2002 0.77
86 Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther 2007 0.77
87 Preparation of peptide-loaded dendritic cells for cancer immunotherapy. Mol Biotechnol 2003 0.76
88 Immune monitoring. Cancer Treat Res 2005 0.76
89 Adenovirus vaccine immunotherapy targeting WT1-expressing tumors. Expert Opin Biol Ther 2010 0.76
90 DNA and RNA modified dendritic cell vaccines. World J Surg 2002 0.76
91 Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunol Res 2011 0.76
92 Disparities in breast carcinoma treatment in Asian/Pacific Islander women. A challenge to the provider. Cancer 2002 0.75
93 Designing effective vaccines for colorectal cancer. Immunotherapy 2014 0.75
94 Bridging the information gap between health and the environment in North Carolina. J Public Health Manag Pract 2013 0.75
95 The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori. Cancer Epidemiol Biomarkers Prev 2005 0.75
96 Proteomics for monitoring immune responses to cancer vaccines. Curr Opin Mol Ther 2003 0.75
97 Recent areas of development for dendritic cell vaccines. Cancer Chemother Biol Response Modif 2003 0.75
98 A review of the health impacts of barium from natural and anthropogenic exposure. Environ Geochem Health 2014 0.75